Development of the sporadic inclusion body myositis physical functioning assessment

Muscle and Nerve

Volumn 54, Issue 4, 2016, Pages 653-657

  DeMuro, Carla ^a   Lewis, Sandy ^a   Lowes, Linda ^b   Alfano, Lindsay ^b   Tseng, Brian ^c   Gnanasakthy, Ari ^a  

^a RTI HEALTH SOLUTIONS   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

development; patient reported outcomes; physical functioning; qualitative research; sporadic inclusion body myositis

Indexed keywords

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; FEMALE; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL ASSESSMENT; HUMAN; INCLUSION BODY MYOSITIS; MALE; OBSERVATIONAL STUDY; PATIENT-REPORTED OUTCOME; PHYSICIAN; PRIORITY JOURNAL; RATING SCALE;

EID: 84986571301     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.25079     Document Type: Article

References (11)

1. Fehnel S, DeMuro C, McLeod L, Coon C, Gnanasakthy A. US FDA patient-reported outcome guidance: great expectations and unintended consequences. Expert Rev Pharmacoecon Outcomes Res 2013;13:441–446.
2. United States Food and Drug Administration. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. Fed Reg 2009;74:65132–65133.
3. Studenski S. Bradypedia: is gait speed ready for clinical use? J Nutr Health Aging 2009;13:878–880.
4. Hilton-Jones D, Miller A, Parton M, Holton J, Sewry C, Hanna M. Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM |workshop, London, 13 June 2008. Neuromuscul Disord 2010;20:142–147.
5. Boeije H. A purposeful approach to the constant comparative method in the analysis of qualitative interviews. Quality Quantity 2002;36:391–409.
6. Amato AA, Barohn RJ. Inclusion body myositis: old and new concepts. J Neurol Neurosurg Psychiatry 2009;80:1186–1193.
7. Johns Hopkins Medicine. Inclusion body myositis. http://www.hopkinsmedicine.org/myositis/myositis/ibm.html. Accessed January 17, 2013.
8. Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007;6:620–631.
9. Lowes LP, Alfano L, Viollet L, Rosales XQ, Sahenk Z, Kaspar BK, et al. Knee extensor strength exhibits potential to predict function in sporadic inclusion-body myositis. Muscle Nerve 2012;45:163–168.
10. Jackson C, Barohn R, Gronseth G, Pandya S, Herbelin L. Inclusion Body Myositis Functional Rating Scale: a reliable and valid measure of disease severity. Muscle Nerve 2008;37:473–476.
11. Donatti C, Wild D, Hareendran A. The Use Of Conceptual Models, Conceptual Frameworks, and Endpoint Models to Support Label Claims Of Treatment Benefit Using Patient Reported Outcomes. Ispor Connect 2008;14:9–12.